Institut Pasteur Medical Center
Paris, 75015, France
Location status: Recruiting
Location contact
Patrick HOCHEDEZ, Dr
CONTACT
NCT Number: NCT07097480
Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.
The objective of the study is to investigate the prevalence of STLV-1 and SFV infections following a nonhuman primate bite.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Paris, 75015, France
Location status: Recruiting
Patrick HOCHEDEZ, Dr
CONTACT
Nonhuman primates (NHPs) constitute an important reservoir of infectious agents, some of which have emerged in human populations as deadly pathogens. Human exposure to the biological fluids of NHPs - particularly through bites - can result in the transmission of several viruses. Only the rabies virus is currently targeted by post-exposure prophylaxis following an injury caused by an NHP.
Compared to other individuals exposed to nonhuman primates (NHPs), travelers have two unique characteristics. First, they are typically exposed only once to simian infectious agents, in contrast to the repeated exposure experienced by other at-risk groups. If exposure results in an infection event, travelers may spread these infectious agents to geographic areas where they do not normally circulate.
To address the following main objective: to study the prevalence of STLV-1 and SFV infections following a nonhuman primate bite. The study plans to include subjects who have been recently bitten as well as those with a history of nonhuman primate bites. Blood and saliva samples will be collected from the subjects.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Specific criteria for genetic analyses:
Exclusion criteria
Blood samples of 40 ml will be taken.
Saliva samples will be collected
Time frame: 17 months
Detection of specific antibodies and viral DNA against both viruses in blood.
Time frame: 17 months
The study of associations between STLV-1 and SFV infection and demographic characteristics (age, sex) and those linked to the HNP bite (severity of injury, HNP species) will be analyzed by Fisher's exact test and the Mann-Withney test.
Time frame: 17 months
Measurement of viral markers (SFV RNA and DNA, STLV-1 DNA, virus-specific IgM and IgG) in blood and saliva.
Time frame: 17 months
Determination of complete viral sequences and integration sites in the human genome.
Contact information is provided by the study sponsor or research team.
Institut Pasteur
Industry
Virus Transmission to People Recently Bitten or With a History of Monkey Bites "SIMVIR"
Acronym: SIMVIR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07013474
COVID-19, COVID-19 Infection
Canoga Park, California, United States
View Trial DetailsNCT06679140
COVID-19, COVID-19 SARS-CoV-2 Infection
Little Rock, Arkansas, United States
View Trial DetailsNCT07670468
BKV Infection, CMV Infection
Seoul, South Korea
View Trial DetailsNCT07565090
Filoviridae Infections, Hemorrhagic Fever, Ebola
Washington D.C., District of Columbia, United States
View Trial Details